Abstract
Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of
Original language | English (US) |
---|---|
Pages (from-to) | 1622-1632 |
Number of pages | 11 |
Journal | European Respiratory Journal |
Volume | 42 |
Issue number | 6 |
DOIs | |
State | Published - Dec 1 2013 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine